A new study published in the journal of Cureus showed that duloxetine significantly reduced neuropathic pain and improved ...

Oral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI ® with one-third of patients with relapsed/refractory multiple myeloma progression-free for ...

Braftovi and Erbitux plus chemotherapy improved survival without progression over standard therapy in BRAF V600E-mutant mCRC ...

The active substance of Ezmekly, mirdametinib, is a selective, non-competitive mitogen-activated protein kinase 1 and 2 (MEK 1/2) inhibitor. By inhibiting MEK, mirdametinib blocks the proliferation ...

Current treatment options have improved survival rates but have not provided a cure. Eventually, initial therapies stop ...

Adding dostarlimab to platinum-based chemotherapy and niraparib improved PFS in patients with advanced ovarian cancer.

EBC-129 has been granted FDA fast track designation for the treatment of pancreatic ductal adenocarcinoma, paving the way for ...

RxDx assay as a companion diagnostic to identify c-Met protein expression in non-squamous NSCLC patients eligible for treatment with Emrelis.

Relacorilant/nab-paclitaxel significantly improved PFS and OS vs nab-paclitaxel alone in platinum-resistant ovarian cancer.

New research suggests that an antibody-drug conjugate may offer practice-changing, patient-friendly treatment of blastic ...

Research findings increasingly indicate close associations between autoimmune thyroid disease and rheumatic disease.

European Commission approves Roche’s Evrysdi tablet to treat spinal muscular atrophy: Basel Thursday, June 5, 2025, 09:00 Hrs [IST] Roche announced that the European Commission ...